Compare Organon & Co. Common Stock (OGN) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Vanguard Ultra Short Bond ETF — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Vanguard Ultra Short Bond ETF trades at $49.48 (market cap $10.20B). The key difference: Vanguard Ultra Short Bond ETF is far larger — about 2.8× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Vanguard Ultra Short Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Vanguard Ultra Short Bond ETF for 64 Days on average.
| OGN | VUSB | |
|---|---|---|
Market Cap | $3.62B | $10.20B |
Volume | 2,892,999 | 1,227,697 |
Sector | Health | Leveraged / Inverse |
52-Week High | $13.81 | $50.03 |
52-Week Low | $5.70 | $49.41 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
VUSB is trading at $49.475, showing minimal daily movement with a slight decline of 0.01%. Technical indicators signal a bearish trend with moving averages and oscillators in sell territory. The ETF maintains consistent dividend distributions, with recent payments of $0.17-0.18 per share. Market sentiment is influenced by Federal Reserve interest rate expectations, positioning short-term bond ETFs favorably amid potential rate increases.
The outlook for VUSB remains cautious due to bearish technical signals and interest rate sensitivity. Investment opportunity exists for investors seeking short-term bond exposure with regular income, though risks include Fed policy shifts and market volatility. The ETF's stability and dividend consistency provide defensive characteristics in uncertain rate environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
